RPRadek Pohnán

Radek Pohnán

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Radek Pohnán has a total of 104 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prevalence of new onset diabetes mellitus among patients with pancreatic ductal adenocarcinoma: a population-based study

    by Jan Bures, Katerina Hejcmanova, Tereza Dianova, Ondrej Ngo, Darina Kohoutova, Radek Pohnan, Jan Skrha, Stepan Suchanek, Petr Urbanek, Ladislav Dusek, et al.

    Background: Pancreatic ductal adenocarcinoma (PDAC) has remained one of the most serious malignancies and is still a leading cause of cancer-related deaths worldwide. Great attention has been paid to the relationship between diabetes mellitus and PDAC. The aim of our study was to analyse the mutual association of PDAC and diabetes mellitus in the entire population of the Czech Republic within a 5-year period. Methods: The incidence of PDAC in 2018-2022 was estimated based on the individual population data from the Czech National Cancer Registry. Another data source, the National Registry of Reimbursed Health Services that collects data from health insurance companies, was used to identify individuals recently diagnosed with diabetes mellitus. For the purpose of this study, diagnosis of new-onset of diabetes mellitus was defined as the time of the first prescription of any antidiabetic drug or another related health care service. Subsequently, patients diagnosed with PDAC in 2022 were followed retrospectively to see if they had been diagnosed with diabetes mellitus in the last five years before diagnosis of pancreatic cancer. Results: In 2022, 2,189 patients aged 60 years or older were diagnosed with pancreatic cancer. New-onset diabetes was observed in 17.4% within five years prior to diagnosis, with the highest occurrence (12.4%) within the last three years. Among patients aged 60-74 years, the respective proportions were 14.4% within three years and 5.7% four to five years prior to pancreatic cancer diagnosis. Conclusion: The incidence of pancreatic cancer in the Czech Republic is among the highest in Europe. One-fifth of PDAC cases are diagnosed following new-onset diabetes mellitus in patients over sixty. Unintended significant weight loss combined with new-onset diabetes thus must not be overlooked, as these can be early signs of PDAC. An individualised diagnostic work-up should follow without any unnecessary delay. Note: The study was presented in part, as an abstract and moderated poster, at the 32nd United European Gastroenterology Week, Vienna, October 12-15, 2024 [ UEG Journal, 2024(12), S8: 565-566]. Key Summary: Summarise the established knowledge on this subject Pancreatic ductal adenocarcinoma (PDAC) is□one of the most lethal□gastrointestinal cancers, with an increasing incidence worldwide. The mutual association between□PDAC and diabetes mellitus has been recognized for decades. While diabetes mellitus can be a risk factor for pancreatic cancer, new-onset diabetes□often serves as□an early sign of PDAC. Different types of diabetes mellitus□are□associated with PDAC. Type 2 diabetes is the most common (characterized by increased insulin secretion and receptor resistance). Secondary diabetes mellitus in non-malignant pancreatic diseases (e.g., chronic pancreatitis) involves a reduction of islet-cell mass, leading to decreased insulin secretion□but□normal insulin sensitivity.□Type 3c diabetes associated with PDAC is considered□a paraneoplastic syndrome, characterized by decreased insulin secretion and increased insulin resistance.□ What are the significant and/or new findings of this study? Our study was based on data from Czech national healthcare registries (2018– 2022). The age-standardized incidence rate of PDAC in the Czech Republic was 24.6 per 100,000 population in 2023. In 2022, 2,189 patients over the age of 60 were diagnosed with PDAC. New-onset diabetes mellitus was recorded in 12.4% of patients within three years□prior to their□cancer diagnosis. Specifically, among□patients aged 60–74 years, this proportion was 14.4% (three years prior to diagnosis),□reaching a total of□20.1% over a five-year period. Unintended significant weight loss combined with new-onset diabetes must not be overlooked, as these can be early signs of PDAC. An individualized diagnostic work-up should follow without□unnecessary delay

  • Open Access

    Hemopneumothorax After Carotid Endarterectomy

    by Simona Formánková, Michael Rousek, Jiří Pudil, Radek Pohnán

    Spontaneous hemopneumothorax (SHP) is a rare condition characterized by the accumulation of air and blood in the pleural cavity without prior trauma. We present a case of a patient who underwent carotid endarterectomy for carotid artery stenosis. Two days postoperatively, she developed sudden respiratory distress, hypotension, tachycardia, and a decrease in hemoglobin levels. A chest X‐ray revealed a massive left‐sided hemopneumothorax. A chest tube was inserted, but no active bleeding source was identified on subsequent imaging. Despite initial stabilization, the patient required intubation and underwent video‐assisted thoracoscopic surgery for residual hemothorax and empyema. She fully recovered. In this case report, we provide an overview of the diagnostic and treatment options for SHP. As SHP is a potentially life‐threatening condition, we emphasize the importance of including it in the differential diagnosis of sudden patient deterioration. In our case, the patient had undergone vascular surgery; however, the cause of hemorrhagic shock was unexpectedly SHP.

  • Open Access

    Intraoperative Imaging in Hepatopancreatobiliary Surgery

    by Tereza Husarova, William M. MacCuaig, Isabel S. Dennahy, Emma J. Sanderson, Barish H. Edil, Ajay Jain, Morgan M. Bonds, Molly W. McNally, Katerina Menclova, Jiri Pudil, et al.

    Hepatopancreatobiliary surgery belongs to one of the most complex fields of general surgery. An intricate and vital anatomy is accompanied by difficult distinctions of tumors from fibrosis and inflammation; the identification of precise tumor margins; or small, even disappearing, lesions on currently available imaging. The routine implementation of ultrasound use shifted the possibilities in the operating room, yet more precision is necessary to achieve negative resection margins. Modalities utilizing fluorescent-compatible dyes have proven their role in hepatopancreatobiliary surgery, although this is not yet a routine practice, as there are many limitations. Modalities, such as photoacoustic imaging or 3D holograms, are emerging but are mostly limited to preclinical settings. There is a need to identify and develop an ideal contrast agent capable of differentiating between malignant and benign tissue and to report on the prognostic benefits of implemented intraoperative imaging in order to navigate clinical translation. This review focuses on existing and developing imaging modalities for intraoperative use, tailored to the needs of hepatopancreatobiliary cancers. We will also cover the application of these imaging techniques to theranostics to achieve combined diagnostic and therapeutic potential.


  • Combination of endoluminal and external vacuum-assisted closure system in management of complicated anastomotic leak after esophageal resection – a case report

    by Z. Vacková, K. Kmochova, N. Brodyuk, R. Pohnan, P. Urbanek, M. Zavoral, S. Suchanek

    Aims Esophageal leakage of postoperative esophagogastrostomy is considered a life-threatening condition due to the possible development of mediastinitis. The technique of vacuum-assisted closure (VAC) is an established method in treatment of infected surgical wounds, but also has been used endoscopically to heal intraluminal leaks. In this case report, we present a successful use of combined rendezvous external and endoluminal VAC therapy of a large postoperative anastomotic leak with mediastinitis after esophageal resection. Methods Case report Results In April 2020, a 57-year-old man underwent esophageal resection for T1b adenocarcinoma related to Barrett’s esophagus. On postoperative day 6, the patient developed posterior mediastinitis with severe sepsis due to the dehiscence of the esophago-gastroanastomosis (EGA) which was diagnosed on CT scan. Surgical revision with drainage was performed immediately and external VAC therapy was initiated together with Danish Seal stent inserted into the esophagus to prevent leakage. Three weeks later, the stent was extracted but the fistula persisted. Therefore, the esophageal VAC therapy (E-VAC) was introduced into the EGA defect. During the following 43 days, a total of 12 E-VAC exchanges (every 3-4 days) were performed concurrently with the ongoing external VAC therapy. The patient recovered clinically, the fistula has obliterated and mediastinitis healed. A follow-up upper GI endoscopy 2 months and one year later showed a completely healed EGA. Conclusions Combination of endoluminal and external VAC system can be an effective method in complex treatment of a large postoperative leak. Supported by the project MO1012 and Cooperatio. Article published online: 14 April 2023 © 2023. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

  • Rare Variant of the Replaced Common Hepatic Artery During Pancreaticoduodenectomy

    by Michael Rousek, Pavel Zaruba, Miroslav Ryska, Radek Pohnan


  • Status of robotic and minimally invasive foregut tumour surgery

    by Radek Pohnán, Jaroslav Pažin, Jaroslav Kalvach, Daniel Langer, Jan Hadač, Miroslav Ryska

    Summary: Esophagectomy and gastrectomy are essential curative methods in the treatment of non-metastatic malignancies of the esophagus and stomach. Video-assisted minimally invasive resections of the esophagus and stomach have demonstrated surgical and oncological safety and can be used as part of multimodal treatment strategy. Robot-assisted surgical operations are a new technology in the field of mini-invasive upper gastrointestinal surgery. The technical advantages of robotic systems combining minimally invasive surgical approaches with the possibility of multi-element articulation of robotic instruments in the operating field lead to a worldwide expansion of robotic centers. Further technological development can be expected to enhance support and facilitation of minimally invasive surgery and to further reduction of the surgical stress while adhering to the criteria of radical oncosurgery. Key words: minimally invasive surgery – laparoscopy – robotic surgery – esophagectomy – gastrectomy

  • Robotic-assisted surgery for colorectal and hepatopancreatobiliary neoplasms

    by Daniel Langer, Michal Vočka, Jaroslav Kalvach, Jaroslav Pažin, Miroslav Ryska, Radek Pohnán

    Summary: Introduction: The Czech Republic belongs to countries under significant strain due to malignant tumours. Despite the changes introduced in the therapy of gastrointestinal malignancies, radical removal of the tumour holds a crucial position in the mutimodal therapeutic process and is irreplaceable nowadays. From the beginning of the third millennium, minimally invasive surgery of abdominal tumours is being expanded with robotic-assisted procedures. The aim of this paper is to assess the benefits of robotic-assisted surgery in the treatment of colorectal and hepatopancreatobiliary neoplasms and to present the results of a non-randomized study with prospectively collected data from robotically assisted rectal cancer surgeries. Material and method: The authors summarize studies published in the PubMed, EMBASE, Medline and Cochrane Library databases that compare robotic and laparoscopic approaches in the treatment of colorectal and hepatopancreatobiliary malignancies, and present the results of their own non-randomized study. 204 patients with rectal cancer (<15 cm from the anal verge) who underwent robotic-assisted surgery at our department between 1 January 2016 and 31 December 2020 were included in the study. All demographic, clinical and oncological data were prospectively obtained and analysed. The data were analysed using descriptive statistic methods. Results: 204 patients with rectal cancer of whom 138 were men and 66 were women underwent robotic surgery at our department during the five-year period. In 97 (47.5%) cases the disease was dia­gnosed in an advanced stage (stage III and IV of the TNM classification). 18 patients had synchronous liver metastases and 2 patients had pulmonary metastases at the time of the dia­gnosis. The liver-first approach was indicated in 8 (44.4%) patients, two patients underwent a radical resection of liver lesions together with the primary neoplasm in one surgery. Total mesorectal excision was performed in 136 patients with extraperitoneal disease, partial mesorectal excision was performed in 68 cases. 18 complications were documented. Clinically relevant anastomotic leak requiring intervention occurred in 5 (3.6%) cases. One patient died due to decompensation of chronic toxonutritive liver disease. Local recurrence was documented in 6 patients, half of them underwent radical resection. Conclusion: Surgical therapy holds a crucial position in the treatment of colorectal and hepatopancreatobiliary neoplasms and represents the only potentially curative procedure in multimodal therapy. Robotic-assisted therapy has become a routine therapeutic modality for colorectal and hepatopancreatobiliary malignancies worldwide. Da Vinci assisted surgeries prevail in the surgical treatment of rectal cancer at the authors’ workplace as well as at some foreign centres. Compared to open and laparoscopic resections of rectal carcinoma, robotic-assisted operations achieve the same clinical and oncological results with a lower rate of complications. Key words: robotic surgery – colorectal cancer – liver malignancies – pancreatic carcinoma

  • Malignant prolactinoma – can a long-term survival be affected?

    by Kaeřina Menclová, Tomáš Novák, David Netuka, Mikuláš Kosák, Radek Pohnán

  • Surgical treatment of benign mediastinal neurogenic tumors - a 7-year analysis

    by Radek Pohnán, Jaroslav Herzinger, Petr Vaněk, Josef Mališ, Alice Tašková, Davit Netuka